Nkarta (NKTX) Income towards Parent Company (2019 - 2026)
Nkarta's (NKTX) quarterly Income towards Parent Company came in at -$34.0 million in Q1 2026, up 9.81% year-on-year from -$31.0 million in Q1 2025, and down 0.85% quarter-over-quarter from -$33.8 million in Q4 2025.
Nkarta (NKTX) Income towards Parent Company (2019 - 2026) Analysis & Trends
Nkarta's Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$34.0 million for Q1 2026.
- On a quarterly basis, Income towards Parent Company rose 9.81% year-over-year to -$34.0 million in Q1 2026; TTM through Mar 2026 was -$190.5 million, a 42.28% decrease from a year earlier, with the FY2025 full-year figure at -$257.9 million, down 99.55% from the prior year.
- Income towards Parent Company eased to -$34.0 million in Q1 2026 per NKTX's latest filing, from -$33.8 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$26.6 million in Q1 2022 and bottomed at -$180.2 million in Q2 2023.
- The 5-year median for Income towards Parent Company is -$37.7 million (2025), against an average of -$65.4 million.
- Across the five-year window, Income towards Parent Company plunged 514.86% in 2022 and surged 82.94% in 2024, its largest moves.
- Year by year, Income towards Parent Company stood at -$36.1 million in 2022, then decreased by 20.49% to -$43.5 million in 2023, then climbed by 29.15% to -$30.8 million in 2024, then declined by 9.58% to -$33.8 million in 2025, then decreased by 0.85% to -$34.0 million in 2026.
- Per Business Quant, the three latest NKTX Income towards Parent Company figures stand at -$34.0 million (Q1 2026), -$33.8 million (Q4 2025), and -$60.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Nkarta | 168.94 Mn | 168.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.04 Mn |
| Dec 31, 2025 | -33.75 Mn |
| Sep 30, 2025 | -60.52 Mn |
| Jun 30, 2025 | -62.15 Mn |
| Mar 31, 2025 | -37.74 Mn |
| Dec 31, 2024 | -30.80 Mn |
| Sep 30, 2024 | -34.57 Mn |
| Jun 30, 2024 | -30.75 Mn |
| Mar 31, 2024 | -60.42 Mn |
| Dec 31, 2023 | -43.47 Mn |
| Sep 30, 2023 | -169.42 Mn |
| Jun 30, 2023 | -180.22 Mn |
| Mar 31, 2023 | -36.65 Mn |
| Dec 31, 2022 | -36.08 Mn |
| Sep 30, 2022 | -88.41 Mn |
| Jun 30, 2022 | -145.81 Mn |
| Mar 31, 2022 | -26.59 Mn |
| Dec 31, 2021 | -23.97 Mn |
| Sep 30, 2021 | -39.69 Mn |
| Jun 30, 2021 | -23.71 Mn |